Servier: Clinical Trials

22 trials sponsored by Servier, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 4 active not recruiting, 4 not yet recruiting, 3 recruiting. 22 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 222Completed 7, Active not recruiting 4, Not yet recruiting 4, Recruiting 3, Unknown 2, Suspended 1, Terminated 1
Phase 12Not yet recruiting 2
Phase 31Active not recruiting 1

Follow Servier: new trials by email

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation
S243249 600mg, S243249 400mg, S243249 450mg - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingServier802026-10-202026-09-03
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase 1 / Phase 2Not yet recruitingServier642026-09-152026-07-22
Ivosidenib as Post-HSCT Maintenance for AML
Ivosidenib, Placebo - IDH1 Mutation, Acute Myeloid Leukemia (AML)
Phase 2RecruitingMassachusetts General Hospital752026-01-162026-10-05
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
Trifluridine/tipiracil, Bevacizumab - Metastatic Colorectal Cancer
Phase 2Not yet recruitingGERCOR - Multidisciplinary Oncology Cooperative Group1622025-09-012025-07-17
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
Nal-IRI, Ciprofloxacin, Paclitaxel - PDAC - Pancreatic Ductal Adenocarcinoma
Phase 2Not yet recruitingGERCOR - Multidisciplinary Oncology Cooperative Group2062025-07-012025-07-01
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Lonsurf, Oxaliplatin, Panitumumab - Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma
Phase 2RecruitingUNICANCER732025-03-212025-12-10
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Ivosidenib - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
Phase 2Active not recruitingServier122023-10-102025-12-09
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Trifluridine/Tipiracil, Oxaliplatin, FOLFOX regimen - Gastric Adenocarcinoma, Esophagus Adenocarcinoma
Phase 2Active not recruitingUNICANCER1182023-06-232026-07-24
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer
Phase 2SuspendedGruppo Oncologico del Nord-Ovest4772023-05-172026-02-03
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Venetoclax, Decitabine - Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 2RecruitingMontefiore Medical Center912022-03-232026-01-05
Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients
Trifluridine/Tipiracil, Oxaliplatin - Colorectal Adenocarcinoma, Oesogastric
Phase 2TerminatedGERCOR - Multidisciplinary Oncology Cooperative Group12022-02-072023-09-18
Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma
Combination of Lonsurf® and Irinotecan - Cholangiocarcinoma
Phase 2CompletedHeinrich-Heine University, Duesseldorf282021-10-282024-03-27
Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas
nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA) - Pancreatic Cancer, Metastasis
Phase 2UnknownUniversity of Cologne1502021-10-102024-01-12
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
trifluridine/tipiracil - Breast Neoplasm, Chemotherapy Effect
Phase 2CompletedBorstkanker Onderzoek Groep522020-09-252026-05-22
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
Liposomal Irinotecan, Carboplatin, Capecitabine - Esophageal Cancer
Phase 2Active not recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)3202019-05-012026-08-21
Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma
Onivyde, Paclitaxel - Squamous Cell Carcinoma
Phase 2CompletedFederation Francophone de Cancerologie Digestive1062019-03-072025-01-08
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
Liposomal Irinotecan, Fluorouracil, Folinic Acid - Oncology, Neuroendocrine Carcinoma
Phase 2CompletedThe Christie NHS Foundation Trust582018-11-132024-12-30
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B) - Adenocarcinoma Metastatic, Biliary Tract Cancer
Phase 2CompletedAIO-Studien-gGmbH932018-01-242025-10-01
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
nal-IRI, 5-FU, leucovorin - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
Phase 2CompletedAIO-Studien-gGmbH1002017-10-242022-05-18
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Prednisone, Vincristine, Daunorubicin - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Phase 2 / Phase 3Active not recruitingSt. Jude Children's Research Hospital7902017-03-292026-06-17

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Leukemia, Myeloid, Acute (4)  ·  Cholangiocarcinoma (2)  ·  Colorectal Neoplasms (2)  ·  Leukemia, Myelomonocytic, Chronic (2)  ·  Neoplasm Metastasis (2)  ·  Recurrence (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma Of Esophagus (1)  ·  Bile Duct Neoplasms (1)  ·  Biliary Tract Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Carcinoma, Squamous Cell (1)  ·  Cardiotoxicity (1)  ·  Colonic Neoplasms (1)

Interventions

Fluorouracil (7)  ·  Leucovorin (7)  ·  Oxaliplatin (6)  ·  irinotecan sucrosofate (6)  ·  trifluridine tipiracil drug combination (6)  ·  Bevacizumab (2)  ·  Capecitabine (2)  ·  Gemcitabine (2)  ·  Irinotecan (2)  ·  Nivolumab (2)  ·  Paclitaxel (2)  ·  Trastuzumab (2)  ·  ivosidenib (2)  ·  Asparaginase (1)  ·  Bortezomib (1)

Countries

France (6)  ·  Germany (6)  ·  United States (3)  ·  Netherlands (2)  ·  Australia (1)  ·  Italy (1)  ·  Japan (1)  ·  United Kingdom (1)

Top investigators

A. Elise van Leeuwen-Stok, PhD (1)  ·  Amir T Fathi, MD (1)  ·  Arndt Vogel, Prof. (1)  ·  Christoph Roderburg, Prof. (1)  ·  Dirk Waldschmidt (1)  ·  Florian Gebauer, MD (1)  ·  Georg Hess, MD (1)  ·  Henning Ebelt, MD (1)  ·  Hiroto Inaba, MD, PhD (1)  ·  Jan M Prins, MD, PhD (1)

Results publications

PMID 21638157, PMID 31646981, PMID 32029495, PMID 37217885, PMID 37287870, PMID 38762353, PMID 38843469, PMID 38870977, PMID 39316768, PMID 40017682, PMID 40147791, PMID 40876084, PMID 42154791

NIH funding

2016 (2), 2025 (2), 2014 (1), 2019 (1)